These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35172721)

  • 41. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).
    Waksman R; Bertrand O; Driesman M; Gruberg L; Rossi J; Mehta S; Swymelar S; Dvir D; Xue Z; Torguson R
    J Interv Cardiol; 2013 Apr; 26(2):107-13. PubMed ID: 23240743
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
    Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
    Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy.
    Sardi GL; Lindsay J; Waksman R
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):614-20. PubMed ID: 22581418
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anticoagulant Use Among Patients With End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention: An Analysis From the National Cardiovascular Data Registry.
    Washam JB; Kaltenbach LA; Wojdyla DM; Patel MR; Klein AJ; Abbott JD; Rao SV
    Circ Cardiovasc Interv; 2018 Feb; 11(2):e005628. PubMed ID: 29432119
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
    Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
    Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined Use of Bivalirudin and Radial Access in Acute Coronary Syndromes Is Not Superior to the Use of Either One Separately: Meta-Analysis of Randomized Controlled Trials.
    Mina GS; Gobrial GF; Modi K; Dominic P
    JACC Cardiovasc Interv; 2016 Aug; 9(15):1523-31. PubMed ID: 27491601
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
    Valgimigli M; Frigoli E; Leonardi S; Vranckx P; Rothenbühler M; Tebaldi M; Varbella F; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andó G; Ferrario M; Limbruno U; Garbo R; Sganzerla P; Russo F; Nazzaro M; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Ferrante G; Santarelli A; Sardella G; de Cesare N; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Heg D; Jüni P;
    Lancet; 2018 Sep; 392(10150):835-848. PubMed ID: 30153988
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials.
    Cavender MA; Sabatine MS
    Lancet; 2014 Aug; 384(9943):599-606. PubMed ID: 25131979
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of unfractionated heparin or bivalirudin on patients with stable coronary artery disease undergoing percutaneous coronary intervention.
    Lima FV; Gruberg L; Aslam U; Ramgadoo M; Clase K; Trevisan A; Jeremias A
    J Interv Cardiol; 2018 Apr; 31(2):177-184. PubMed ID: 29205487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bivalirudin Versus Heparin Monotherapy in Elderly Patients With Myocardial Infarction: A Prespecified Subgroup Analysis of the VALIDATE-SWEDEHEART Trial.
    Wester A; Attar R; Mohammad MA; Isma N; James S; Omerovic E; Erlinge D; Koul S
    Circ Cardiovasc Interv; 2020 Apr; 13(4):e008671. PubMed ID: 32216471
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bivalirudin during primary PCI in acute myocardial infarction.
    Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
    N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
    Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL
    Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bivalirudin started during emergency transport for primary PCI.
    Steg PG; van 't Hof A; Hamm CW; Clemmensen P; Lapostolle F; Coste P; Ten Berg J; Van Grunsven P; Eggink GJ; Nibbe L; Zeymer U; Campo dell' Orto M; Nef H; Steinmetz J; Soulat L; Huber K; Deliargyris EN; Bernstein D; Schuette D; Prats J; Clayton T; Pocock S; Hamon M; Goldstein P;
    N Engl J Med; 2013 Dec; 369(23):2207-17. PubMed ID: 24171490
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bivalirudin use in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Insights from the prospective, multi-centre EUROVISION registry.
    Limbruno U; Picchi A; Galli S; Huber K; Lipiecki J; Bernstein D; Deliargyris E; Anthopoulos P; Nienaber C; Hamon M
    Acute Card Care; 2014 Dec; 16(4):127-31. PubMed ID: 25101656
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of bivalirudin as the foundation anticoagulant during percutaneous peripheral interventions.
    Eres A
    J Invasive Cardiol; 2006 Mar; 18(3):125-8. PubMed ID: 16598112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bivalirudin versus heparin, without glycoprotein inhibition, in percutaneous coronary intervention: A comparison of ischemic and hemorrhagic outcomes over 10years.
    Chaudry HI; Curran TB; Andrus BW; Conley SM; DeVries JT
    Cardiovasc Revasc Med; 2018; 19(3 Pt B):338-342. PubMed ID: 29055661
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.
    Shah A; Feldman DN
    Vasc Health Risk Manag; 2012; 8():115-23. PubMed ID: 22399856
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bivalirudin versus heparin in women undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials.
    Saad M; Nairooz R; Rashed A; Abdelaziz HK; Mentias A; Abbott JD
    Cardiovasc Revasc Med; 2017 Sep; 18(6):418-424. PubMed ID: 28291727
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention.
    Shah R; Jovin IS; Chaudhry A; Haji SA; Askari R; Dennis MM; Berzingi C; Rao SV
    Catheter Cardiovasc Interv; 2019 Feb; 93(2):241-247. PubMed ID: 30269393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.